Beth Israel team tackles new approach to leukemia, breast cancer; Michigan investigators ID prostate cancer biomarker;

> Investigators at the Cancer Research Institute at Beth Israel Deaconess Medical Center identified an inhibitor of the Pin1 enzyme that can block multiple cancer pathways and simultaneously target cancer stem cells. The investigators say this approach could be promising for acute promyelocytic leukemia (APL) and triple negative breast cancer. Release

> University of Michigan researchers say they have found a biomarker that may be an important advance in diagnosing and treating prostate cancer. Release

> A new study concludes that gene therapy is superior to using stem cells from a partially matched donor in treating "bubble boy" disease. Release

Suggested Articles

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.

Brigham and Women’s Hospital scientists linked a noncoding RNA to atherosclerosis in a discovery that could aid in the development of new heart drugs.